DEVELOPING COUNTRY VACCINE MANUFATURES NETWORK (DCVMN) AND BUTANTAN, REVISITED

Abstract

Fifteen years had passed and the aims of DCVMN, sponsored by WHO, is being maintained alive and active by a few of its members, resulting in national impact, avoiding the spread from endemics to pandemics, affecting populations in developing and developed countries. Even though, leading programs shared in different countries by members of DCVMN have a limited impact. Related to this, recent initiatives of powerful large pharma industry, aware of the world impact in preventing infectious diseases, move to secure its participation in a world market of about 40 billion euros/year, maintained, in part, by national public health programs, supported by international agencies and foundations, with a central role in funding vaccines for the developing countries. The majority of the World population is in Developing Countries, with a direct impact in maintaining the world market. It is difficult to quantify what is philanthropy and what represents market interest, but maintaining the developing world as dependent.